Long-Acting HIV Treatment May Help Drug-Resistant Cases

Long-Acting HIV Treatment, Drug-Resistant HIV, HIV Therapy, Lenacapavir, Cabotegravir, Antiretroviral Therapy, HIV Viral Suppression, HIV Drug Resistance, HIV Clinical Research, UCSF, Infectious Diseases, HIV Care, Long-Acting Antiretrovirals, JAMA Network Open, cabotegravir, HIV clinical trial, HIV treatment research, undetectable HIV viral load, injectable HIV treatment, HIV care

Key Takeaways A UCSF study found that long-acting lenacapavir plus cabotegravir maintained viral suppression in 46 people with HIV. All…

Epilepsy Drugs May Interact With Hormonal Contraceptives

Night Shift Work Alters Key Circadian Gene Expression

SARS-CoV-2, COVID-19, rhinovirus, common cold, pediatric COVID, HEROS study, interferon response, respiratory viruses, viral interference, immune priming, National Jewish Health, COVID protection, children immunity, respiratory infections, non-invasive research

Study Reveals Cold May Impact SARS-CoV-2 Infection Rates

The Unexpected Protective Role of Rhinoviruses in COVID-19 A groundbreaking study from National Jewish Health.

COVID-19

Heart, Lung, & Brain Risks Persist in COVID-19 Survivors

A French nationwide study reveals that individuals hospitalized with COVID-19 remain at an increased risk.

vaccines

How COVID-19 and Vaccines Differ in Heart Inflammation

A team of international researchers led by the Max Delbrück Center for Molecular Medicine in.

Long Covid

Long COVID: Extended Paxlovid Treatment Offers Hope

A new case series by UC San Francisco (UCSF) suggests that an extended course of.

Trending

Long-Acting HIV Treatment May Help Drug-Resistant Cases

Long-Acting HIV Treatment, Drug-Resistant HIV, HIV Therapy, Lenacapavir, Cabotegravir, Antiretroviral Therapy, HIV Viral Suppression, HIV Drug Resistance, HIV Clinical Research, UCSF, Infectious Diseases, HIV Care, Long-Acting Antiretrovirals, JAMA Network Open, cabotegravir, HIV clinical trial, HIV treatment research, undetectable HIV viral load, injectable HIV treatment, HIV care

Key Takeaways A UCSF study found that long-acting lenacapavir plus cabotegravir maintained viral suppression in 46 people with HIV. All…

COVID-19

SARS-CoV-2, COVID-19, rhinovirus, common cold, pediatric COVID, HEROS study, interferon response, respiratory viruses, viral interference, immune priming, National Jewish Health, COVID protection, children immunity, respiratory infections, non-invasive research

Study Reveals Cold May Impact SARS-CoV-2 Infection Rates

The Unexpected Protective Role of Rhinoviruses in COVID-19 A groundbreaking study from National Jewish Health has revealed an intriguing phenomenon:…

Heart, Lung, & Brain Risks Persist in COVID-19 Survivors

A French nationwide study reveals that individuals hospitalized with COVID-19 remain at an increased risk of death and organ-related complications…

How COVID-19 and Vaccines Differ in Heart Inflammation

A team of international researchers led by the Max Delbrück Center for Molecular Medicine in Berlin has identified distinct immune…

Health and Wellness

Smoking, Loneliness, Smoking Cessation, Social Isolation, Psychosocial Health, Tobacco Use, Respiratory Medicine, Public Health, Older Adults, Tobacco Addiction, Smoking and Social Isolation, European Respiratory Society, Preventive Medicine, Behavioral Health, Healthcare Professionals, smoking-related health effects, smoking cessation support, effects of smoking, respiratory health, public health, smoking and mental health

Smoking and Loneliness Linked in Large European Study

Key points: A Europe-wide study of more than 50,000 adults found that current smokers reported greater loneliness than non-smokers. Smokers…

Women’s Healthcare Advances Through FemTech

Key Summary FemTech has grown from menstrual tracking and fertility apps into a major women's healthcare technology sector. The industry…

Mazdutide Shows Significant Weight Loss in Phase 3 Trial

Key Summary Mazdutide, a dual GLP-1 and glucagon receptor agonist, achieved 16.65% mean weight loss in adults with obesity. 84.3%…